Clinical Trial Update: Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406) [Phase 3]

View source ↗

Summary

Phase 3 study using an environmental exposure chamber to assess the onset of action of ciclesonide nasal spray for seasonal allergic rhinitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Seasonal Allergic Rhinitis

Drugs mentioned

• Ciclesonide nasal spray (ciclesonide)

Snippet

Sponsor: AstraZeneca | Conditions: Rhinitis, Allergic, Seasonal, Hay Fever | Phase 3 | Status: COMPLETED